HILO-HF Registry: High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure

Acute Heart Failure Clinical Trial

Official title:

High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03110042
• Other study ID #: HILO-HF Registry
• Status: Completed
• Start date: November 2016
• Est. completion date: April 2019

Study information

• Verified date: April 2019
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The HILO-HF Registry is a single centre registry that will be performed to provide information on the usual baseline oxygen saturation (SpO2) in patients presenting to ED with a primary ED diagnosis of AHF

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: April 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients >40 years of age presenting to the ED with AHF

• With or without tested BNP

• With or without admission to hospital for treatment of HF\

• Patients must be recruited within the first 24 hours of presenting to the ED.

Exclusion Criteria:

• Patients on home oxygen

• Patients with known prior hypercapnic failure (PaCO2>50 mmHg)

• Asthma

• Primary pulmonary hypertension

• Patients requiring urgent positive pressure ventilation or intubation or on >10 L/min oxygen

Related Conditions & MeSH terms

• Acute Heart Failure
• Heart Failure

Locations

Country	Name	City	State
Canada	University of Alberta Hospital / Mazankowski Alberta Heart Institute	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in blood oxygen saturation levels from baseline to 72 hours		72 hours
Secondary	Dyspnea on visual analogue scale (VAS) to 72 hours		72 hours
Secondary	Change in global symptoms using Patient Global Assessment (PGA) measure to 72 hours		72 hours
Secondary	Change in Peak Expiratory Flow		72 hours
Secondary	Rate of patients with Worsening Heart Failure		7 days
Secondary	30-day composite clinical event (all-cause mortality, HF readmission, days alive and out of hospital)		30days